GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRadimed Corp (NAS:IRMD) » Definitions » COGS-to-Revenue

iRadimed (iRadimed) COGS-to-Revenue : 0.24 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is iRadimed COGS-to-Revenue?

iRadimed's Cost of Goods Sold for the three months ended in Mar. 2024 was $4.21 Mil. Its Revenue for the three months ended in Mar. 2024 was $17.60 Mil.

iRadimed's COGS to Revenue for the three months ended in Mar. 2024 was 0.24.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. iRadimed's Gross Margin % for the three months ended in Mar. 2024 was 76.08%.


iRadimed COGS-to-Revenue Historical Data

The historical data trend for iRadimed's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRadimed COGS-to-Revenue Chart

iRadimed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.26 0.23 0.23 0.23

iRadimed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.24 0.22 0.23 0.24

iRadimed COGS-to-Revenue Calculation

iRadimed's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=15.404 / 65.562
=0.23

iRadimed's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4.21 / 17.598
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRadimed  (NAS:IRMD) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

iRadimed's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 4.21 / 17.598
=76.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


iRadimed COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of iRadimed's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


iRadimed (iRadimed) Business Description

Traded in Other Exchanges
Address
1025 Willa Springs Drive, Winter Springs, FL, USA, 32708
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.
Executives
Roger E. Susi director, 10 percent owner, officer: CEO, President, Chairman C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
James B Hawkins director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Anthony Vuoto director
Monty K Allen director
Hilda Frederique Scharen-guivel director 440 PALM ISLAND SE, CLEARWATER BEACH FL 33767
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Christopher K. Scott officer: CHIEF FINANCIAL OFFICER & SECR C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Brent Johnson officer: Exec. VP. Sales & Marketing 4900 HOPYARD RD, SUITE 210, PLEASITAN CA 94588
Steven M. Nardi officer: VP MANUFACTURING C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Louis S. Waldman officer: CONTROLLER C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Leslie L Mcdonnell director, officer: Chief Exec Officer & Director 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Francis X. Casey officer: VP OF REG AND QUAL ASSURANCE C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
John K Mccreery officer: Chief Operating Officer IRADIMED CORP, 1025 WILLA SPRINGS BLVD, WINTER SPRINGS FL 32708
Jonathan Kennedy director INTERSIL CORPORATION, 1001 MURPHY RANCH ROAD, MILPITAS CA 95035
Serge Novovich director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708

iRadimed (iRadimed) Headlines